Keywords: Tumour marker, ovarian cancer, adnexal mass, human epididymis 4, cancer antigen 125
From 2001 to 2005, a quarter of the women were randomized to annual cancer antigen 125
(CA-125) screening, with ultrasound follow-up and oncology referral as indicated; a quarter to annual transvaginal ultrasound screening and referral; and a half to no screening, as a control.
The serum levels of cancer antigen 125
(CA-125), interleukin 18(IL-18) in the peritoneal fluids and cyclooxygenase-2 (COX-2) mRNA expression levels in the ectopic endometrium were detected in this study.
Cancer antigen 125
(CA125) was first iden- tified through the immunological detection of epi- thelial ovarian carcinoma, and is known to bind to monoclonal antibody OC125.
This was vastly superior to the 35% positive predictive value in the same samples of cancer antigen 125
, the present gold standard clinical biomarker.
Food and Drug Administration for diagnostic use, is designed to detect cancer antigen 125
(CA 125) levels in human serum and plasma.
32) Findings from recent large clinical trials of serum cancer antigen 125
(CA 125) and transvaginal ultrasonography demonstrated that these screening modalities do not confer a benefit for mortality.
Carbohydrate antigen 125 or cancer antigen 125
(CA-125), also known as mucin 16 (MUC16), is a member of mucin glycoproteins, which contains 22,000 amino acids.
Results from the last--the PLCO (Prostate, Lung, Colorectal, and Ovarian) trial, which tested screening with cancer antigen 125
(CA125) and transvaginal ultrasound--were recently reported (JAMA 2011;305:2295-303).
Ovarian cancer patients should have their cancer antigen 125
(CA-125) levels checked regularly.
Large-scale screening for ovarian cancer with a combination of transvaginal ultrasound and cancer antigen 125
is a feasible strategy that can accurately identify early cancers, a large U.
Urinary Bcl-2 was more accurate in identifying ovarian cancer than was cancer antigen 125
(CA125), which is currently considered to be the accepted standard for ovarian cancer detection, Dr.
A case of benign multicystic mesothelioma of the peritoneum (BMMP) is presented uniquely characterized by an elevated serum carbohydrate antigen 19-9 (CA-19-9) and biopsy positive immunostaining for CA-19-9, carcinoembryonic antigen (CEA), and cancer antigen 125
Further testing protocols include at least a yearly transvaginal ultrasound scan and a serum cancer antigen 125
(CA 125) test.